Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising
agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We …

Background Programmed cell death protein 1 (PD-1) pathway blockade with immune
checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma …

Hepatocellular carcinoma (HCC) is the most common malignancy worldwide, and is
especially common in China. A total of 70%–80% of patients are diagnosed at an advanced …

Background & Aims We investigated the efficacy and safety of immune checkpoint inhibitor
(ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who received ICI-based …

Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …

Abstract Background Immune checkpoints inhibitors (ICIs) have emerged as a treatment
option for several malignancies. Nivolumab, pembrolizumab, nivolumab plus ipilimumab …

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death
worldwide. A first-line standard of care, sorafenib results in median overall survival of 12 …

Importance Immune checkpoint inhibitors (ICIs) have yielded conflicting results in
hepatocellular carcinoma (HCC). The overall effect of ICIs compared with standard therapies …

Simple Summary Immune checkpoint inhibitors represent a promising treatment choice in
many kind of tumours, including hepatocellular carcinoma (HCC). In this review, we provide …

Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell
death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte …